arrow
A

Andrew D.J. Pearson

LifeArc
H指数:70
被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Paediatric therapeutic development workshop on desmoplastic small round cell tumours

儿科治疗药物开发研讨会关于纤维性小圆细胞肿瘤

2026-10-140
OAAI
Paediatric therapeutic development workshop on osteosarcoma

儿童骨肉瘤治疗开发研讨会

2026-08-180
OA
Paediatric therapeutic development workshop on medulloblastoma

儿童髓母细胞瘤治疗开发研讨会

2026-07-090
OA
Paediatric Therapeutic Development Workshop on rhabdomyosarcoma

儿童横纹肌肉瘤治疗研发研讨会

2026-06-130
OAAI
Paediatric Therapeutic Development Workshop on rhabdoid tumours

横纹肌样瘤儿科治疗开发研讨会

2026-02-120
OAAI
International neuroblastoma risk group consortium: a model of networking for rare cancers
2025-08-250
OAAI
Paediatric strategy forum for medicinal product development of cyclin-dependent kinase inhibitors in children and adolescents ACCELERATE in collaboration with the European Medicines Agency With participation of the Food and Drug Administration

儿童及青少年周期蛋白依赖性激酶抑制剂药物开发儿科策略论坛ACCELERATE,与欧洲药品管理局合作,并邀请美国食品药品监督管理局参与。

2025-07-110
PRE
Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer

儿童和青少年癌症PI3-K、mTOR、AKT和GSK3β 抑制剂药物开发儿科战略论坛

2024-08-010
PRE
Addition of AMXT1501 (polyamine uptake inhibitor) plus DFMO (polyamine synthesis inhibitor) to standard-of-care chemotherapy/anti-GD2 antibody in the TH-MYCN mouse neuroblastoma model, enhances efficacy compared to addition of DFMO alone
2023-12-010
PRE
Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
2023-09-016
OAAI
Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
2022-12-019
OAAI
Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting

难治性,复发性或进行性神经母细胞瘤的早期临床试验资格和反应评估标准: 美国国家癌症研究所临床试验计划会议的共识声明

CANCER
IF5.1
2022-09-135
OAAI
Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
2022-09-0112
OA
ACCELERATE-Five years accelerating cancer drug development for children and adolescents
2022-05-0130
OA
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration

儿童和青少年癌症患者嵌合抗原受体T细胞药物产品开发儿科战略论坛与欧洲药品管理局合作,食品和药物管理局参与加速

2022-01-0127
OA
Pediatric Cancer Data Commons: Federating and Democratizing Data for Childhood Cancer Research

儿科癌症数据共享: 儿童癌症研究的联合和民主化数据

2021-12-0125
OA
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration
2021-11-0136
OA